Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial
Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has received EUR 1.5 million in funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”).
This is the second installment of the EUR 3.5 million in unconditional funding agreed with Atlas allowing the Company to reach the topline data of the Phase 2, Part B of the KALAHARI trial, expected by the end of this year.
Under the terms of the amended Subscription Agreement, Atlas has waived the market capitalization and liquidity conditions for up to EUR 3.5 million in mandatorily convertible bonds to be issued before the topline data is received by the end of 2023.
Under the Funding Program, Atlas has committed to up to EUR 20 million in funding over a 24-month period, of which it has now subscribed to EUR 10.5 million, leaving a remainder of EUR 9.5 million of which the conditions are waived for EUR 1 million.
Tom Graney, CEO of Oxurion, said: “Oxurion remains confident in reaching the key catalyst of reporting the topline data from the KALAHARI trial this year without additional capital, thanks to the sustained support from Atlas. The KALAHARI trial is evaluating Oxurion’s THR-149 versus market leader aflibercept, and in this trial, Oxurion hopes to demonstrate the superior efficacy of THR-149 in treating the up to 50% of patients with diabetic macular edema (DME) for whom the current standard of care is suboptimal. DME remains the leading cause of blindness for working-aged people, and we believe that THR-149 holds the promise of addressing this large unmet need. We look forward to sharing those topline results this year.”
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Chief Executive Officer
Tel: +32 16 75 13 10
Chief Business Officer
Tel: +32 16 75 13 10
Mary T. Conway
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
TGS Shareholders Approve the Merger Plan with PGS1.12.2023 17:09:37 CET | Press release
OSLO, Norway (1 December 2023) - Reference is made to the joint stock exchange announcement on 18 September 2023 by TGS ASA ("TGS" or the "Company," OSE: TGS) and PGS ASA ("PGS," OSE: PGS) regarding the combination of the two companies (the "Merger") to establish the premier energy data company, as well as subsequent announcements on 25 and 30 October 2023 regarding, respectively, the execution of the definitive merger agreement and notices for extraordinary general meetings for approval. An extraordinary general meeting in TGS was held today at 16:00 hours (Oslo time) as a virtual meeting. All proposals on the agenda were approved with requisite majorities, including the merger plan dated 25 October 2023 and the corresponding share capital increase in the Company. As separately announced by PGS earlier today, the merger has also been approved by the extraordinary general meeting in PGS. As a consequence, the decision to approve the merger will now be filed with the Norwegian Register
Festi hf.: Buyback program week 48 – end of buyback1.12.2023 16:58:38 CET | Press release
In week 48 2023, Festi purchased in total 19,260 own shares for total amount of 3,409,020 ISK as follows: WeekDateTimePurchased shareSahre pricePurchase price 48 29.nov 11:51:24 19.260 177 3.409.020 19.2603.409.020 The execution of the buyback program is in accordance with the Act on Public Limited Companies No 2/1995, Article 5 of the Regulation of the European parliament and of the Council No. 596/2014, on market abuse, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the purchase Festi held 3,226,966 own shares or 1.06% of issued shares. Festi has now bought in total 3,246,226 own shares (1.07% of issued shares) for 599,999,945 ISK and has finished the buyback. This announcement of purchase of own shares is in accordance with the buyback program announced 21 July 2023 to Nasdaq OMX Iceland. The program envisages the buyback of a total of 3,500,000 own shares or 1.15% of the issued shares, with the cap of 600 million I
Fastsættelse af rentetrigger for rentetilpasningsobligationer1.12.2023 16:35:59 CET | pressemeddelelse
Fastsættelse af rentetrigger for rentetilpasningsobligationer DLR har afsluttet obligationssalget i forbindelse med refinansieringen af rentetilpasningslån med årlig rentetilpasning pr. 2. januar 2024 og har fastsat niveauet for rentetriggeren på de 1-årige rentetilpasningsobligationer i DKK, der kan udløse forlængelse af løbetiden ved næste års refinansiering. Flere oplysninger om rentetriggere kan ses på www.dlr.dk/investor. Oplysninger om obligationssalget i forbindelse med refinansieringerne kan ses samme sted. Spørgsmål vedrørende rentetrigger kan rettes til Fondschef Nikolaj Knudsen på telefon 33 42 07 38. Med venlig hilsen DLR Kredit A/S Vedhæftet fil Fastsættelse af rentetrigger 2023-12-01
Hydro completes sale to Glencore1.12.2023 16:30:00 CET | Press release
Hydro has completed the USD 1.11 billion transaction for the sale of 30 percent interest in the Brazilian alumina refinery Hydro Alunorte and Hydro’s 5 percent interest in the bauxite producer Mineracão Rio do Norte (MRN), together with Vale’s 40 percent stake in MRN. “We are looking forward to work with Glencore to further develop Alunorte. Glencore has broad industrial experience within metals and mining, which adds to the significant progress our bauxite and alumina area has made to bring down the footprint of alumina production. This enables Hydro to strengthen our position in low-carbon aluminium,” says President and CEO, Hilde Merete Aasheim. Hydro and Glencore will continue efforts to reduce carbon emissions from Alunorte through the fuel switch project that aims to substitute fuel oil with LNG, and the electrification of boilers. This will bring Alunorte to the first decile on the global carbon curve already in 2025, positioning Alunorte as a leading supplier of low-carbon alum
Hydro fullfører salget til Glencore1.12.2023 16:30:00 CET | Pressemelding
Hydro har fullført transaksjonen på 1,11 milliarder USD for salg av 30 prosent eierandel i det brasilianske aluminaraffineriet Hydro Alunorte og Hydros eierandel på 5 prosent i bauksittprodusenten Mineracão Rio do Norte (MRN), samt Vales eierandel på 40 prosent i MRN. – Vi ser frem til å samarbeide med Glencore for å videreutvikle Alunorte. Glencore har bred industriell erfaring innen metaller og gruvedrift, noe som forsterker den betydelige fremgangen forretningsområdet vårt for bauksitt og alumina vårt har gjort for å redusere fotavtrykket fra aluminaproduksjonen. Dette gjør Hydro i stand til å styrke vår posisjon innen lavkarbonaluminium, sier konsernsjef Hilde Merete Aasheim. Hydro og Glencore vil fortsette arbeidet med å redusere karbonutslippene fra Alunorte gjennom drivstoffbytteprosjektet som har som mål å erstatte tungolje med LNG, og elektrifisering av fyrkjeler. Dette vil bringe Alunorte til den første desilen på den globale karbonkurven allerede i 2025, og posisjonere Aluno